Market Research Logo
Region: Europe
Category: Country Overviews

Europe Country Overviews

(129 reports matching your criteria)
  • Pharmaceuticals and Healthcare Report - Serbia Q4 2014

    ...Although criticised bythe media for its new policy of lowering medicine prices, Babic believes it means that the organisation isnot working for pharmaceutical companies but for the benefit of the Serbian people. The implementation ofthe ... Read More

  • Pharmaceuticals and Healthcare Report - Slovakia Q4 2014

    ...autumn this year. Medical fees byhospitals and doctors are symptomatic of the chronic inefficiency of healthcare funding within Slovakia. With the healthcare system set to come under the complete control of the Slovak state, funding ... Read More

  • Pharmaceuticals and Healthcare Report - Spain Q4 2014

    ...follow suit until 2018. Regardless of callsmade by companies for the implementation of a system that adequately rewards innovation and supportsinvestment in future medicines, the government will likely continue with its cost containment measures bytargeting ... Read More

  • Pharmaceuticals and Healthcare Report - Belarus Q4 2014

    ...Ukraine andRussia and absolute erosion of consumer purchasing power. Geopolitical tension between Russia andUkraine will continue to impact trading volumes in the region, with a full-blown conflict posing a seriousthreat to the Belarusian economy. Belarus ... Read More

  • Pharmaceuticals and Healthcare Report - Ukraine Q4 2014

    ...severe devaluation of the hryvnia inthe country, drugmakers can expect a challenging business environment as capital outflow restrictions havebeen recently implemented. Import taxes, pricing restrictions, and exchange rate volatility presentsignificant risks to drugmakers operating in ... Read More

  • Romania Pharmaceutical Report - Q2, 2014

    ...to RON 3bn (EUR 679.8mn) in Q2/2014, returning to growth after having declined on an annual basis for three consecutive quarters. In volume terms, the market also rose by 3.2% y/y in Q2, recovering from ... Read More

  • Pharmaceuticals and Healthcare Report - Netherlands Q4 2014

    ...austerity measures to meet the terms of EUbudget criteria and further restrictions on drug expenditure look likely, particularly on essential medicines. Although healthcare expenditure continues to increase (in local currency terms), we maintain our view ... Read More

  • Pharmaceuticals and Healthcare Report - Portugal - Q3 2014

    ...to growth in 2015, while pharmaceuticals will not return to growth until 2019. This isbecause while Portugal exited its bailout programme in May 2014 without the need for a new financialpackage, government austerity measures are ... Read More

  • Pharmaceuticals and Healthcare Report Q3 2014 - Moldova

    ...with the EU inJune 2014, which would strengthen the business environment and improve the regulatory structure andaccess to the pharmaceutical market in the country. Moldova is undertaking a reform of its healthcaresector with the World ... Read More

  • Pharmaceuticals and Healthcare Report Q3 2014 - Spain

    ...to drugmakers operating in the country. Despite calls made by companies for theimplementation of a system that adequately rewards innovation and supports investment in futuremedicines, the government is likely to remain committed to fiscal consolidation ... Read More

  • Pharmaceuticals and Healthcare Report Q3 2014 - Lithuania

    ...The upcoming switch to theeuro promises to boost purchasing power and stabilise the pharmaceutical market, albeit at the cost ofincreasing healthcare expenditure. Ceding control of monetary policy to Brussels leaves Lithuania withlittle leeway to increase ... Read More

  • Pharmaceuticals and Healthcare Report Q3 2014 - Serbia

    ...reduce itsdebt burden. However, pharmaceutical spending is also a target for cuts. Local drug makers are set to feelthe worst of these new measures as they cannot compete on cost compared to larger players in ... Read More

  • Pharmaceuticals and Healthcare Report Q3 2014 - Slovakia

    ...agencyTASR. The government added that after adding contributions from the state budget, the total funds that havebeen allocated for developing healthcare infrastructure will be EUR300mn (USD417.3mn). The governmentplans to allocate these funds to projects in ... Read More

  • Pharmaceuticals and Healthcare Report Q3 2014 - Greece

    ...will continue to target the pharmaceutical and healthcare industry to reduce public spending.We highlight, however, that the generic drug sector and private healthcare industry will present somegrowth opportunities in the country. Headline Expenditure Projections Pharmaceuticals: ... Read More

  • Pharmaceuticals and Healthcare Report - Norway Q3 2014

    ...inNorway. In the long term, we believe this will result in stronger downward price pressures on medicinesthat treat long-term chronic medicines, with companies increasingly being required to prove thecost effectiveness of their innovative medicines to ... Read More

  • Pharmaceuticals and Healthcare Report - Ireland Q3 2014

    ...Ireland as one of the highest in Europe. This will have a knock-on effect on government pharmaceutical expenditure, and means that companiesoperating in the country will face ongoing revenue-restricting measures. Meanwhile, we believe the worstof ... Read More

  • Pharmaceuticals and Healthcare Report - Finland Q3 2014

    ...we believe the success of the annual decline in reimbursed medicine prices will result in thegovernment maintaining the generic reference pricing system that is in place. Amplifying price pressures onpatented medicines are the unsystematic price ... Read More

  • Pharmaceuticals and Healthcare Report - United Kingdom Q3 2014

    ...beyond 2014. This drop in spendingreflects the UK government's focus on containing costs within the healthcare sector, and in particularpharmaceutical expenditure. Headline Expenditure Projections Pharmaceuticals: GBP23.32bn (USD36.15bn) in 2013 to GBP22.90bn (USD37.33bn) in 2014;-1.8% in ... Read More

  • Pharmaceuticals and Healthcare Report - Switzerland Q3 2014

    ...consumption levels (as a result of an ageing population) and the population's preference for high-value innovative treatments for chronic diseases over lower-value generic medicines. The government operates a generous medicine reimbursement scheme and the country ... Read More

  • Pharmaceuticals and Healthcare : Belgium Pharmaceuticals and Healthcare Report Q3 2014

    ...highly developed pharmaceutical manufacturing industryis increasingly threatened by cheaper suppliers from Eastern Europe and Asia. Even though percapita spending on pharmaceuticals is relatively high, it is subjected to continual downward pressure, whichtranslates into growth opportunities ... Read More

  • Pharmaceuticals and Healthcare : Estonia Pharmaceuticals and Healthcare Report Q3 2014

    ...in pharmaceutical spending in Estonia as theEstonian government's policy of fiscal restraint continues. Fiscal tightening has lead to pressure on theEstonian Health Insurance Fund to rein in pharmaceutical expenditure through pricing limits, genericprescribing and reference ... Read More

  • Pharmaceuticals and Healthcare : France Pharmaceuticals and Healthcare Report Q3 2014

    ...deficit reduction target of 3.0% of GDP by 2015 - affectingexpenditure on pharmaceuticals and healthcare as a part of the government's fiscal consolidation plans. However, the new government of Manuel Valls has indicated it may ... Read More

  • Pharmaceuticals and Healthcare : Ukraine Pharmaceuticals and Healthcare Report Q3 2014

    ...region. In 2014, owing to the distressed economicsituation in the country, drugmakers can expect a challenging business environment and capital outflowrestrictions. Import taxes, pricing restrictions, and exchange rate volatility present significant risks todrugmakers operating in ... Read More

  • Pharmaceuticals in Sweden

    ...leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Sweden pharmaceuticals market. Includes market size data, textual and graphical analysis of ... Read More

  • Pharmaceuticals in Norway

    ...leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Norway pharmaceuticals market. Includes market size data, textual and graphical analysis of ... Read More

1 2 3 5